I make a donation

ADEN

Genetics-guided antiplatelet monotherapy Vs standard early de-escalation with ticagrelor or prasugrel at 1 month after ACS in patients at risk of bleeding.

En cours

Bourses ACTION & PHRA 2022

Colloquium "La cardiologie préventive : nouveautés" (mardi 1er avril 2025)
Réservez vos places !

La Fondation de l'AP-HP attribue le Grand Prix Scientifique 2024 au Pr Gilles Montalescot

P&R Agenda
Au programme prochainement...

objectif

Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome

date de réalisation

2024

nombre de patients

2468

nombre de centres participants

Multicentric trial (26 french sites)

type de financement

Public (APHP)

Référence

NCT05577988

Autres études

ARGONAUT

En cours

Anticoagulant Regimens Given to achieve thrombus regression and reduce clinical Outcomes among patients with Non device related intra cardiac thrombus : a randomized Assessment Under direct oral antic...

ANCHOR

En cours

Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients

AMPHIBIA

En cours

Acute Myocarditis registry with Prognostic, Histologic, Immunologic, Biological, Imaging and clinical Assessment : The AMPHIBIA registry